Search

Dihydro-alpha-ergocryptine

These two compounds are differentiated in the position of a methyl group. This structural difference is due to a proteinogenic amino acid replacement from leucine to isoleucine. … Alpha-dihydroergocryptine approved drug product is as a part of an ergoloid mixture. To know more about this mixture, please visit [DB01049]

Scorpion (centruroides) immune Fab2 antivenin (equine)

*, *C. l. tecomanus*, and *C. s. suffusus*. … Centruroides (scorpion) Immune F(ab')2 (equine) is a purified preparation of immune globulin F(ab’)2 fragments that are derived from plasma of the horses immunized with venom of *C. noxius*, *C. l. limpidus

Quinupristin

Quinupristin/dalfopristin is a combination of two antibiotics used to treat infections by staphylococci and by vancomycin-resistant Enterococcus faecium.

Pipobroman

An antineoplastic agent that acts by alkylation.

Zomepirac

Zomepirac, formerly marketed as Zomax tablets, was associated with fatal and near-fatal anaphylactoid reactions. The manufacturer voluntarily removed Zomax tablets from the Canadian, US, and UK markets in March 1983.

Neisseria meningitidis group Y capsular polysaccharide tetanus toxoid conjugate antigen

Methazolamide

A carbonic anhydrase inhibitor that is used as a diuretic and in the treatment of glaucoma.

Hydroxycitronellal

Sensitivity to hydroxycitronellal may be identified with a clinical patch test. … Hydroxycitronellal has also been shown to be a dermatologic irritant and allergen, and as a result commercially available products are restricted by the International Fragrance Association (IFRA) to contain

Isoeugenol

Allergic reactivity to Isoeugenol may be identified with a patch test. … It is also a significant dermatologic sensitizer and allergen, and as a result has been restricted to 200 p.p.m. since 1998 according to guidelines issued by the fragrance industry [A34278].

Reteplase

Retavase is a deletion mutein of human tPA formed by deleting various amino acids present in endogenous human tPA. … Retavase is considered a "third-generation" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA.